300 related articles for article (PubMed ID: 15120041)
21. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
22. New initiatives aim to test more cancer drugs for children.
Brower V
J Natl Cancer Inst; 2004 Dec; 96(24):1808-10. PubMed ID: 15601634
[No Abstract] [Full Text] [Related]
23. [New approaches in experimental cancerology: in search of therapeutic models].
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
[No Abstract] [Full Text] [Related]
24. Models of metastasis in drug discovery.
Talmadge JE
Methods Mol Biol; 2010; 602():215-33. PubMed ID: 20012401
[TBL] [Abstract][Full Text] [Related]
25. Genetically engineered models have advantages over xenografts for preclinical studies.
Becher OJ; Holland EC
Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
[TBL] [Abstract][Full Text] [Related]
26. Establishment of human tumor xenografts in immunodeficient mice.
Morton CL; Houghton PJ
Nat Protoc; 2007; 2(2):247-50. PubMed ID: 17406581
[TBL] [Abstract][Full Text] [Related]
27. Tumour-targeted drug and gene delivery: principles and concepts.
Cassidy J; Schätzlein AG
Expert Rev Mol Med; 2004 Sep; 6(19):1-17. PubMed ID: 15387893
[TBL] [Abstract][Full Text] [Related]
28. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
Günzburg WH; Salmons B
Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235
[TBL] [Abstract][Full Text] [Related]
29. New anticancer agents: in vitro and in vivo evaluation.
Zips D; Thames HD; Baumann M
In Vivo; 2005; 19(1):1-7. PubMed ID: 15796152
[TBL] [Abstract][Full Text] [Related]
30. Hydrogen peroxide: a potent cytotoxic agent effective in causing cellular damage and used in the possible treatment for certain tumours.
Symons MC; Rusakiewicz S; Rees RC; Ahmad SI
Med Hypotheses; 2001 Jul; 57(1):56-8. PubMed ID: 11421625
[TBL] [Abstract][Full Text] [Related]
31. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
32. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
33. Has chemotherapy anywhere to go?
Connors TA
Cancer Surv; 1989; 8(3):693-705. PubMed ID: 2701089
[TBL] [Abstract][Full Text] [Related]
34. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
35. Current status of cancer drug development: failure or limited success?
Grindey GB
Cancer Cells; 1990 Jun; 2(6):163-71. PubMed ID: 2201343
[TBL] [Abstract][Full Text] [Related]
36. The tumour microenvironment: a novel target for cancer therapy.
Hanna E; Quick J; Libutti SK
Oral Dis; 2009 Jan; 15(1):8-17. PubMed ID: 18992016
[TBL] [Abstract][Full Text] [Related]
37. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
38. Novel cytotoxic drugs: old challenges, new solutions.
Ismael GF; Rosa DD; Mano MS; Awada A
Cancer Treat Rev; 2008 Feb; 34(1):81-91. PubMed ID: 17905518
[TBL] [Abstract][Full Text] [Related]
39. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
40. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
